|
業務類別
|
-- |
|
業務概覽
|
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. |
| 公司地址
| 3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104 |
| 電話號碼
| +1 267 491-6422 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.carismatx.com |
| 員工數量
| 46 |
| Ms. Natalie McAndrew |
Vice President, Finance, Principal Financial Officer and Principal Accounting Officer |
-- |
31/03/2025 |
| Dr. Michael Klichinsky, PhD,Pharm.D. |
Chief Scientific Officer |
美元 463.00K |
31/03/2025 |
| Mr. Steven Kelly |
Director, President and Chief Executive Officer |
美元 600.00K |
31/03/2025 |
|
|
| Ms. Marella Thorell |
Independent Director |
31/03/2025 |
| Ms. Sohanya Roshan Cheng, M.B.A. |
Independent Director |
31/03/2025 |
| Dr. Briggs W. Morrison, M.D. |
Independent Director |
31/03/2025 |
| Dr. David T. Scadden, M.D. |
Director |
31/03/2025 |
| Mr. Steven Kelly |
Director, President and Chief Executive Officer |
31/03/2025 |
| Dr. John A. Hohneker, M.D. |
Independent Director |
31/03/2025 |
| Mr. Sanford S. Zweifach |
Chairman of the Board |
31/03/2025 |
|
|
|
|
